Arch Scientists Publish Data on the Efficacy and Mechanism

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Arch Scientists Publish Data on the Efficacy and Mechanism of Action of Lead Drug Candidate AB569

TORONTO, ONTARIO--(Marketwired - March 1, 2016) - Arch Biopartners Inc (Arch) or (the Company) (TSX VENTURE:ACH)(OTCBB:FOIFF) announced today that Dr. Daniel Hassett's team at the University of Cincinnati College of Medicine, and its collaborators, have published details regarding the efficacy of AB569 in killing the pathogenic bacterium Pseudomonas aeruginosa ( P. aeruginosa) in the peer-reviewed journal Frontiers in Microbiology . The findings indicate that low doses of acidified nitrite and EDTA (active ingredients of AB569) are highly effective at killing P. aeruginosa . In addition, the article provides information on the drug's mechanism of action.

The published data show that treatment of P. aeruginosa with acidified nitrite plus EDTA had the most dramatic and synergistic effect, with virtually all bacteria killed by 25 mM (aerobic), 15 mM (anaerobic) acidified nitrite and EDTA (1mM, aerobic, anaerobic) at pH 6.5 (pH of the CF airway mucus), respectively.

"Our findings indicate the synergistic killing effect of acidified nitrite and EDTA on P. aeruginosa is so strong at lower doses that we expect no adverse toxicology effects once we test AB569 in a future human trial involving cystic fibrosis (CF) patients with chronic P. aeruginosa lung infections," said Dr. Hassett, Professor, Department of Molecular Genetics, Biochemistry and Microbiology, University of Cincinnati College of Medicine.

"Many patients grow bacteria that are not easily treated with currently available antibiotics," said Dr. Patricia Joseph, Professor of Medicine and Director of the Adult CF Program at the University of Cincinnati College of Medicine. "As bacteria evolve to become antibiotic-resistant (often termed "super-bugs"), we are entering the "post-antibiotic" era of infection management. As a result, CF investigators are looking for alternative treatment options to help control the lung infections that eventually destroy lung tissue and result in death for patients with CF. AB569, which combines acidified sodium nitrite with EDTA, has the potential to be such a therapy. The ability to kill highly problematic bacteria such as P. aeruginosa without evidence of injury to lung tissue is extremely exciting. This is true, not just for CF, but for other lung infections such as chronic obstructive pulmonary disease (COPD)."

Details of these findings are reported in the journal Frontiers in Microbiology . The publication, titled " A Putative ABC Transporter Permease is Necessary for Resistance to Acidified Nitrite and EDTA in Pseudomonas aeruginosa Under Aerobic, Anaerobic, Planktonic or Biofilm Conditions" by McDaniel et. al. can be found at http://journal.frontiersin.org/article/10.338...1/abstract . The paper demonstrates key data on the synergistic effects of acidified nitrite and EDTA (active ingredients of AB569) on destroying P. aeruginosa as well as identifying bacterial properties that confer susceptibility to the drug.

The Company has an exclusive option to license AB569 from the University of Cincinnati.

Orphan Drug Designation for AB569 (sodium nitrite and EDTA)

In November 2015, the U.S. F.D.A. granted orphan drug designation for the combination of the two active ingredients of AB569, sodium nitrite and ethylenediaminetetraacetic acid (EDTA), for the treatment of P. aeruginosa lung infections in patients with CF. AB569 is to be administered to patients as a nebulized (inhaled) solution.

Earlier this month, Arch submitted an orphan drug application for AB569 to the European Medicines Authority. The Company was notified by the EMA on February 22 nd that its application has been validated and is now under review. The review period for the application is expected to end in late May, 2016.

The Clinical Need for a New Treatment for P. aeruginosa Pulmonary Infections

P. aeruginosa is a significant cause of bacterial respiratory infections in patients who have cystic fibrosis (CF) or chronic obstructive pulmonary disease. It is also a common cause of pneumonia.

There are approximately 40,000 CF patients in the U.S. The mean prevalence of CF is approximately 0.74 cases per 10,000 people among 27 European Union countries, which is well below the defined limit for a rare or orphan disease. The mucoid form of P. aeruginosa , often found in CF patients, is a very challenging infection to treat due to its high resistance to both antibiotics and phagocyte-mediated killing. Once patients present with the mucoid form of P. aeruginosa , their overall lung function precipitously declines, resulting in a poor prognosis.

Thus, there is an urgent clinical need for the development of novel effective treatments in this area. AB569 constitutes an innovative potential treatment for dealing with mucoid and nonmucoid P. aeruginosa pulmonary infections that are resistant to traditional antibiotics.

Cystic Fibrosis

CF is an autosomal recessive genetic disease that causes abnormalities of the CF transmembrane conductance regulator (CFTR) protein. CFTR is a critical regulator of sweat, digestive fluids, and mucus production.

CF patients are predisposed to lung infections due to abnormal mucus production in the lungs and airways. P. aeruginosa infects 40% of CF patients between the ages of 6 and 10 years of age. By the age of 17, the frequency of infection increases to 60% and reaches approximately 75% of all CF patients between the ages of 25 and 34.

About Arch Biopartners

Arch Biopartners Inc. is focused on the development of innovative technologies that have the potential to make a significant medical or commercial impact. Arch works closely with the scientific community, universities and research institutions to advance and build the value of select preclinical technologies, develop the most promising intellectual property, and create value for its investors.

Arch has established a diverse portfolio that includes MetaMx, which targets illusive brain tumor initiating cells; AB569, a potential new treatment for Pseudomonas aeruginosa pulmonary infections; and, Metablok, a potential treatment for sepsis and cancer metastasis. MetaMx and AB569 are both on track to enter human clinical trials in late 2016 or early 2017.

For more information on Arch Biopartners, other public documents Arch has filed on SEDAR and its technologies including, please visit www.archbiopartners.com .

The Company has 53,189,679 common shares outstanding.

Forward-Looking Statements

All statements, other than statements of historical fact, in this news release are forward looking statements that involve various risks and uncertainties, including, without limitation, statements regarding the future plans and objectives of the Company. There can be no assurance that such statements will prove to be accurate. Actual results and future events could differ materially from those anticipated in such statements. These and all subsequent written and oral forward-looking statements are based on the estimates and opinions of management on the dates they are made and are expressly qualified in their entirety by this notice. The Company assumes no obligation to update forward-looking statements should circumstances or management's estimates or opinions change.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Arch Biopartners, Inc. Richard Muruve Chief Executive Officer 647-428-7031 info@archbiopartners.com Virtus Advisory Group Inc. Babak Pedram Investor Relations 416-644-5081 bpedram@virtusadvisory.com
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Linkind's Best Buy Push Tests Smart Outdoor Demand

Updated Category News Views 199

Holiday lights have quietly become a year-round hardware category, and Linkind wants a louder seat at the table. The smart-lighting brand says three outdoor products have been in Best Buy stores across the United States since October 17, 2026: permanent exterior lights, decorative string lights, and solar pathway lights. That is a real distribution step, not some grand...

Continue Reading
Swell Partners' Awards Highlight Culture, Not Metrics

Updated Category News Views 26

Recognition Lands in a Crowded Talent Market Two shiny Stevie trophies do not pay payroll, but they can say something useful about a company trying to stand out in the noisy talent-services business. Swell Partners has been named 2026 Company of the Year in Business Services and has seen founder and CEO Cari Gatto receive Best Female CEO of the Year. For a private firm...

Continue Reading
Sokin’s UAE License Turns Expansion Into Real Payments Plumbing

Updated Category News Views 118

Dubai expansion headlines are cheap; regulated local money movement is not. That is why Sokin’s newly approved Dubai Financial Services Authority license deserves more than the usual fintech applause line. The company has paired that approval with AED accounts, local payment rails, a One Za’abeel office and a plan to double its UAE staff over the next year. None of...

Continue Reading
MetaOptics Tests a Real Path Into Secure Imaging Markets

Updated Category News Views 68

Fingerprint scanners have never impressed me much; fooling one is exactly the sort of nuisance that keeps security buyers spending. MetaOptics’ new collaboration with Hong Kong’s ASTRI goes after that uncomfortable problem with a compact nano-optics imaging system built for biometric security and smart sensing. It is a sensible target. It is also, at this stage, a...

Continue Reading
MetaComp's $10M Extension Tests Stablecoin Rails in Trade

Updated Category News Views 21

A ten-million-dollar check is cheap until the licensing bills start arriving. MetaComp has added roughly US$10 million from Tether and Abu Dhabi-based Further Asset Management, taking its Pre-A and Pre-A+ fundraising to about US$45 million. The important bit is not the headline-sized pile of cash. It is where management says the money is going: licences, compliance...

Continue Reading
Esquire Spotlight Puts Trauma Cleanup Work in Focus

Updated Category News Views 88

A national magazine profile is an odd milestone for a business built around other people’s worst days. David Lesaffre, co-owner and operator of T.A.C.T. 48, T.A.C.T. AZ, and T.A.C.T. Fort Worth, has been featured by Esquire in a piece called “The Trauma Cleaners.” The attention is deserved, frankly, because biohazard remediation is one of those necessary services...

Continue Reading
Hagerty's Fifth Film Win Keeps Its Media Engine Humming

Updated Category News Views 57

A lap record, a camera crew, and five straight trophies make a louder statement than another glossy corporate slogan. Hagerty won Best Journalism Film at the 2026 International Motor Film Awards on Nov. 14, held at the Petersen Automotive Museum in Los Angeles. The company has taken that particular award home five years running, powered again by Jason Cammisa and his...

Continue Reading
Housing's Value Equation Is Getting More Complicated

Updated Category News Views 82

A homeowner's insurance bill has become a louder market signal than a granite countertop. Green Builder Media's latest batch of research, publishing and events is aimed squarely at that uncomfortable truth: housing is no longer judged only by the price on the contract. Buyers, builders, lenders and insurers are being pushed to reckon with what a home costs to own, protect...

Continue Reading
HiTHIUM's 8-Hour Storage Pitch Faces Real Grid Tests

Updated Category News Views 61

Eight hours of stored electricity is where the sales brochure meets the ugly parts of the grid. HiTHIUM arrived at RE+ 2026 in Las Vegas, held November 17 through 19, with a broad storage pitch: systems ranging from two to eight hours, lithium-ion and sodium-ion chemistry, plus the software and validation work needed to make a battery plant behave when the local grid gets...

Continue Reading
LevelTen Takes Its Clean-Power Market Model to India

Updated Category News Views 50

India's power market is not a tidy spreadsheet, thankfully. It is a vast, fast-growing grid where data centres, factories and climate exposure are all colliding with a generation mix still dominated by coal. That is why LevelTen Energy's move into Asia-Pacific deserves more than the usual clean-tech applause line. Beginning with a 500 MW clean-energy request for proposals...

Continue Reading

Top 5 Most Recently Viewed Articles

Private Tutoring Insights: Learning from Finland's Education Method

Updated Category News Views 206

Exploring Finland's Educational Principles for Private Tutoring In today's rapidly evolving educational landscape, Tutors International passionately investigates various global education models. One system that stands out is Finland's renowned educational approach, widely admired for its emphasis on holistic learning and well-being. Tutors International's latest analysis...

Continue Reading
Charter Communications and Cox Communications Join Forces

Updated Category News Views 162

Charter Communications Merges with Cox Communications In a pivotal move for the telecommunications industry, Charter Communications and Cox Communications have entered into a definitive agreement to combine their companies. This merger signifies a significant consolidation within the sector, promising advancements in service delivery and enhanced operational efficiency...

Continue Reading
Investor Insights on Dyne Therapeutics: Understanding Risks

Updated Category News Views 568

Understanding the Current Situation of Dyne Therapeutics Dyne Therapeutics, Inc. (NASDAQ: DYN) is currently under scrutiny as Pomerantz LLP investigates potential claims on behalf of investors. The concerns arise regarding whether Dyne and its executives may have engaged in improper securities practices. Investors holding shares or contemplating an entry into the market...

Continue Reading
Scientology's New Campaign Aims to Inspire Global Engagement

Updated Category News Views 116

Scientology Launches Global Welcome Campaign The Church of Scientology International is excited to unveil its innovative Global Welcome to Scientology campaign. This initiative is a powerful effort focused on bringing people together and elevating the human experience through understanding and discovery. Inspiring Discovery Across the Globe With the aim of fostering a...

Continue Reading
Deborah R. Willig Shines in Lawdragon's Prestigious Award List

Updated Category News Views 241

Deborah R. Willig Recognized Among Leading Civil Rights Attorneys Willig, Williams & Davidson proudly announces that Deborah R. Willig, the firm's managing partner, has once again earned a spot in the esteemed Lawdragon 500 list of leading civil rights and plaintiff employment lawyers. This recognition underscores her unwavering commitment to advocating for workers'...

Continue Reading